Navigation Links
AEterna Zentaris Announces Outcome of Management's Strategic Review

QUEBEC CITY, QC, Oct. 2 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (TSX: AEZ; Nasdaq: AEZS), a global biopharmaceutical company focused on endocrine therapy and oncology, will announce today at 11: 00 a.m. Eastern Time, during a live webcast presentation and conference call hosted by President and Chief Executive Officer, David J. Mazzo, Ph.D., the outcome of management's review of the Company's pipeline and business operations along with key elements of the new strategic plan implemented to achieve short-term and long-term success.

David J. Mazzo, President and Chief Executive Officer of AEterna Zentaris stated, "Over the past four months, our Executive Team has been tasked with completing a thorough review of our extensive pipeline and business operations with the goal of creating a strategy optimized for success. As a result of this extensive exercise, we established a harmonized global vision and elucidated our strategic imperatives. Based on a rigorous assessment of the value of our assets, our abilities and resources, the probability of success and return on investment potential of each of our product candidates and our objective to maximize shareholder value, we additionally established a set of priorities and plans to achieve our vision."

During the live webcast, the company will discuss in detail the following fundamentals of their strategic plan.

- AEterna Zentaris is now a multinational company with a clear vision to

eventually become a fully integrated biopharmaceutical company (without

commercial manufacturing). The necessary resources have been identified

and allocated to achieve business success.

- AEterna Zentaris has prioritized its pipeline, developed a partnering

strategy and determined the value of its most immediate assets:


Cetrorelix, currently in a Phase 3 program for benign prostatic

hyperplasia (BPH), is clearly the Company's highest priority, being

the asset with the largest combination of probability of success,

proximity to launch and potential medical and commercial value. The

Company has decided to seek a commercialization partner for

cetrorelix, which, in this indication, has potential for base case

peak annual sales of over $500 million in the United States market

alone. After defining the critical path to registration, the Company

expects to launch cetrorelix in the BPH indication in 2011.

Furthermore, after optimization of formulation and trial design, the

company plans to move into Phase 2b in the endometriosis indication

and will announce timelines relative to this program in the near

future. As was announced in May 2007, the rights to cetrorelix in the

endometriosis indication were regained from Solvay. The decision to

proceed with development was made based on:

a) the proven safety and efficacy of Cetrotide(R)

b) the overall database from preclinical and clinical studies in


c) the large unmet medical needs and commercial opportunity in the

area of endometriosis.

Additionally, as with the BPH indication, AEterna Zentaris will

eventually seek a commercialization partner as cetrorelix has the

potential for base case peak annual sales of approximately

$200 million in the U.S. market alone in the endometriosis



AEterna Zentaris has established its cytotoxic conjugate, AEZS-108,

as its highest earlier-stage priority, and will therefore initiate a

Phase 2 trial with this compound in a both endometrial and ovarian

cancers before year end. The Company feels AEZS-108 has large market

opportunities that could compare to those for doxorubicin.

- The Company provided clarity regarding its partnered development

programs. The Company will minimize internal spend on partnered

programs while continuing to respect its contractual obligations to

support its partners for the development of ozarelix, perifosine,

AEZS-127 and AEZS-130. AEterna Zentaris will employ a "piggy back"

registration strategy to bring these products to market in the

territories where is retains rights as commercial opportunity size


- The Company prioritized the advancement of preclinical and very

early-stage development programs based on risk-adjusted maximum market


- The Company established a clear global partnering strategy moving


- All commercially viable projects will be ideally developed internally

through proof-of-concept in man

- Asia (especially Japan) remains a market of interest for AEZS

- The Company also identified non-core assets and will actively seek to

monetize/divest these assets as a potential source of non-dilutive


- The Company provided updated guidance for the 2007 total expected burn

in a range of $25-$27 million. Additionally, in an effort to ensure

financial flexibility, the Company recently filed a shelf prospectus.

"It has been our guiding principle to communicate the complete picture of AEterna Zentaris as it is and as it is planned to be with updated timelines, priorities, key issues and expectations. After a rigorous review of the projects, risks, plans and commercial opportunities, we are more bullish than ever about the unrealized intrinsic value of AEZS and our ability to unlock it to the benefit of patients and shareholders," concluded Dr. Mazzo.

Conference call and Webcast

Participants may access the live webcast via the Company's website at in the "Investors" section, or by telephone using the following numbers: 416-644-3414, 514-807-8791 or 800-733-7571.

A replay of the webcast will also be available on the Company's website for a period of 30 days.

About AEterna Zentaris Inc.

AEterna Zentaris Inc. is global biopharmaceutical company focused on endocrine therapy and oncology with proven expertise in drug discovery, development and commercialization.

News releases and additional information are available at

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of the Company to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. The Company does not undertake to update these forward-looking statements.

Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
(Date:11/25/2015)... PUNE, India , November 26, 2015 /PRNewswire/ ... The Global Biobanking Market 2016 - 2020 ... biobanks by maintaining integrity and quality in long-term ... and enabling long-term cost-effectiveness. Automation minimizes manual errors ... improves the technical efficiency. Further, it plays a ...
(Date:11/25/2015)... 25, 2015 2 nouvelles études permettent ... les différences entre les souches bactériennes retrouvées dans la ... des êtres humains . Ces recherches  ouvrent une nouvelle ... prise en charge efficace de l,un des problèmes ... chats .    --> 2 nouvelles études ...
(Date:11/25/2015)... HOLLISTON, Mass. , Nov. 25, 2015 /PRNewswire/ ... ), a biotechnology company developing bioengineered organ implants for ... will present at the LD Micro "Main Event" ... p.m. PT. The presentation will be webcast live and ... will also be available at the conference for one-on-one ...
(Date:11/25/2015)... , Nov. 25, 2015 /PRNewswire/ - Aeterna Zentaris Inc. ... its business and prospects remain fundamentally strong and ... (zoptarelin doxorubicin) recently received DSMB recommendation to continue ... following review of the final interim efficacy and ... Primary Endpoint in men with heavily pretreated castration- ...
Breaking Biology Technology:
(Date:10/29/2015)... Oct. 29, 2015 Today, LifeBEAM ... partnership with 2XU, a global leader in technical ... smart hat with advanced bio-sensing technology. The hat ... to monitor key biometrics to improve overall training ... the two companies will bring together the most advanced ...
(Date:10/27/2015)... Synaptics Inc. (NASDAQ: SYNA ), the leader ... adopted the Synaptics ® ClearPad ® Series ... newest flagship smartphones, the Nexus 5X by LG and ... --> --> Synaptics works closely with ... in the joint development of next generation technologies. Together, ...
(Date:10/26/2015)...  Delta ID Inc., a company focused on bringing ... devices, announced its ActiveIRIS® technology powers the iris recognition ... by NTT DOCOMO, INC in Japan ... to include iris recognition technology, after a very successful ... May 2015, world,s first smartphone to have this capability. ...
Breaking Biology News(10 mins):